|
1
|
Guastalla J and Diéras V: The taxanes:
toxicity and quality of life considerations in advanced ovarian
cancer. Br J Cancer. 89(Suppl 3): 16–22. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hagiwara H and Sunada Y: Mechanism of
taxane neurotoxicity. Breast Cancer. 11:82–85. 2004. View Article : Google Scholar
|
|
3
|
Nahleh Z, Pruemer J, Lafollette J and
Sweany S: Melatonin, a promising role in taxane-related neuropathy.
Clin Med Insights Oncol. 28:35–41. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gradishar W: Albumin-bound paclitaxel: a
next-generation taxane. Expert Opin Pharmacother. 7:1041–1053.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mielke S, Sparreboom A and Mross K:
Peripheral neuropathy: a persisting challenge in paclitaxel-based
regimes. Eur J Cancer. 42:24–30. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Postma T, Vermorken J, Liefting A, Pinedo
H and Heimans J: Paclitaxel-induced neuropathy. Ann Oncol.
6:489–494. 1995.
|
|
7
|
Freilich R, Balmaceda C, Seidman A, Rubin
M and DeAngelis L: Motor neuropathy due to docetaxel and
paclitaxel. Neurology. 47:115–118. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Verstappen C, Postma T, Geldof A and
Heimans J: Amifostine protects against chemotherapy-induced
neurotoxicity: an in vitro investigation. Anticancer Res.
24:2337–2341. 2004.PubMed/NCBI
|
|
9
|
Makino H: Treatment and care of
neurotoxicity from taxane anticancer agents. Breast Cancer.
11:100–104. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pisano C, Pratesi G, Laccabue D, et al:
Paclitaxel and cisplatin-induced neurotoxicity: a protective role
of acetyl-l-carnitine. Clin Cancer Res. 15:5756–5767.
2003.PubMed/NCBI
|
|
11
|
Loven D, Levavi H, Sabach G, Zart R,
Andras M, Fishman A, Karmon Y, Levi T, Dabby R and Gadoth N:
Long-term glutamate supplementation failed to protect against
peripheral neurotoxicity of paclitaxel. Eur J Cancer Care (Engl).
18:78–83. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Markman M: Prevention of
paclitaxel-associated arthralgias and myalgias. J Support Oncol.
1:233–234. 2003.PubMed/NCBI
|
|
13
|
Rogério F, Teixeira SA, de Rezende AC, de
Sá RC, de Souza Queiroz L, De Nucci G, Muscará MN and Langone F:
Superoxide dismutase isoforms 1 and 2 in lumbar spinal cord of
neonatal rats after sciatic nerve transection and melatonin
treatment. Brain Res Dev Brain Res. 154:217–225. 2005.PubMed/NCBI
|
|
14
|
Chang H, Ling E, Chen C, Lue H, Wen C and
Shieh J: Melatonin attenuates the neuronal NADPH-d/NOS expression
in the nodose ganglion of acute hypoxic rats. J Pineal Res.
32:65–73. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lissoni P, Paolorossi F, Ardizzoia A,
Barni S, Chilelli M, Mancuso M, Tancini G, Conti A and Maestroni G:
A randomized study of chemotherapy with cisplatin plus etoposide
versus chemoendocrine therapy with cisplatin, etoposide and the
pineal hormone melatonin as a first-line treatment of advanced
non-small cell lung cancer patients in a poor clinical state. J
Pineal Res. 23:15–19. 1997. View Article : Google Scholar
|
|
16
|
Lissoni P, Tancini G, Barni S, Paolorossi
F, Ardizzoia A, Conti A and Maestroni G: Treatment of cancer
chemotherapy-induced toxicity with the pineal hormone melatonin.
Support Care Cancer. 5:126–129. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Capizzi R: Protection of normal tissues
from the cytotoxic effects of chemotherapy by amifostine (ethyol):
clinical experiences. Semin Oncol. 21(Suppl 11): 8–15.
1994.PubMed/NCBI
|
|
18
|
Ng T, Ngan H, Cheng D and Wong L: The
effect of amifostine on the in vitro cytotoxicity of
chemotherapeutic agents in three epithelial ovarian carcinoma cell
lines. Gynecol Oncol. 75:194–197. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
DiPaola R and Schuchter L: Neurologic
protection by amifostine. Semin Oncol. 26(2 Suppl 7): 82–88.
1999.PubMed/NCBI
|
|
20
|
Gelmon K, Eisenhauer E, Bryce C, Tolcher
A, Mayer L, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yau J, et
al: Randomized phase II study of high-dose paclitaxel with or
without amifostine in patients with metastatic breast cancer. J
Clin Oncol. 17:3038–3047. 1999.PubMed/NCBI
|
|
21
|
Van den Brande J, Nannan Panday V, Hoekman
K, Rosing H, Huijskes R, Verheijen R, Beijnen J and Vermorken J:
Pharmacologic study of paclitaxel administered with or without the
cytoprotective agent amifostine, and given as a single agent or in
combination with epirubicin and cisplatin in patients with advanced
solid tumors. Am J Clin Oncol. 24:401–403. 2001.
|
|
22
|
Lorusso D, Ferrandina G, Greggi S,
Gadducci A, Pignata S, Tateo S, Biamonte R, Manzione L, Di Vagno G,
Ferrau' F and Scambia G; Multicenter Italian Trials in Ovarian
Cancer Investigators. Phase III multicenter randomized trial of
amifostine as cytoprotectant in first-line chemotherapy in ovarian
cancer patients. Ann Oncol. 14:1086–1093. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hilpert F, Stähle A, Tomé O, Burges A,
Rossner D, Späthe K, Heilmann V, Richter B and du Bois A;
Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer
Study Group. Neuroprotection with amifostine in the first-line
treatment of advanced ovarian cancer with
carboplatin/paclitaxel-based chemotherapy – a double-blind,
placebo-controlled, randomized phase II study from the
Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) ovarian cancer
study group. Support Care Cancer. 13:797–805. 2005.PubMed/NCBI
|
|
24
|
Van Deventer H and Bernard S: Use of
gabapentin to treat taxane-induced myalgias. J Clin Oncol.
17:434–435. 1999.PubMed/NCBI
|
|
25
|
Nguyen V and Lawrence H: Use of gabapentin
in the prevention of taxane-induced arthralgias and myalgias. J
Clin Oncol. 22:1767–1769. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saif M, Syrigos K, Kaley K and Isufi I:
Role of pregabalin in treatment of oxaliplatin-induced sensory
neuropathy. Anticancer Res. 30:2927–2933. 2010.PubMed/NCBI
|
|
27
|
Tassone D, Boyce E, Guyer J and Nuzum D:
Pregabalin: a novel gamma-aminobutyric acid analogue in the
treatment of neuropathic pain, partial-onset seizures, and anxiety
disorders. Clin Ther. 29:26–48. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Frampton J and Foster R: Pregabalin: in
the treatment of postherpetic neuralgia. Drugs. 65:111–118. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Frampton J and Scott L: Pregabalin: in the
treatment of painful diabetic peripheral neuropathy. Drugs.
64:2813–2820. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shneker B and McAuley J: Pregabalin: a new
neuromodulator with broad therapeutic indications. Ann
Pharmacother. 39:2029–2037. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Saif M and Hashmi S: Successful
amelioration of oxaliplatin-induced hyperexcitability syndrome with
the antiepileptic pregabalin in a patient with pancreatic cancer.
Cancer Chemother Pharmacol. 61:349–354. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Porzio G, Aielli F, Verna L, Porto C,
Tudini M, Cannita K and Ficorella C: Efficacy of pregabalin in the
management of cetuximab-related itch. J Pain Symptom Manage.
32:397–398. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mir O, Alexandre J, Tran A, Durand J, Pons
G, Treluyer J and Goldwasser F: Relationship between GSTP
Ile(105)Val polymorphism and docetaxel-induced peripheral
neuropathy: clinical evidence of a role of oxidative stress in
taxane toxicity. Ann Oncol. 20:736–740. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cascinu S, Catalano V, Cordella L,
Labianca R, Giordani P, Baldelli A, Beretta G, Ubiali E and
Catalano G: Neuroprotective effect of reduced glutathione on
oxaliplatin-based chemotherapy in advanced colorectal cancer: a
randomized, double-blind, placebo-controlled trial. J Clin Oncol.
20:3478–3483. 2002. View Article : Google Scholar
|
|
35
|
Hidaka T, Shima T, Nagira K, Ieki M,
Nakamura T, Aono Y, Kuraishi Y, Arai T and Saito S: Herbal medicine
shakuyaku-kanzo-to reduces paclitaxel-induced painful
peripheral neuropathy in mice. Eur J Pain. 13:22–27. 2009.
|
|
36
|
Yamamoto K, Hoshiai H and Noda K: Effects
of shakuyaku-kanzo-to on muscle pain from combination
chemotherapy with paclitaxel and carboplatin. Gynecol Oncol.
81:333–334. 2001.
|
|
37
|
Yoshida T, Sawa T, Ishiguro T, Horiba A,
Minatoguchi S and Fujiwara H: The efficacy of prophylactic
Shakuyaku-Kanzo-to for myalgia and arthralgia following
carboplatin and paclitaxel combination chemotherapy for non-small
cell lung cancer. Support Care Cancer. 17:315–320. 2009.
|
|
38
|
Fujii K, Okamoto S, Saitoh K, Sasaki N,
Takano M, Tanaka S, Kudoh K, Kita T, Tode T and Kikuchi Y: The
efficacy of Shakuyaku-Kanzo-to for peripheral nerve
dysfunction in paclitaxel combination chemotherapy for epithelial
ovarian carcinoma. Gan To Kagaku Ryoho. 31:537–540. 2004.
|
|
39
|
Markman M, Kennedy A, Webster K, Kulp B,
Peterson G and Belinson J: Use of low-dose oral prednisone to
prevent paclitaxel-induced arthralgias and myalgias. Gynecol Oncol.
72:100–101. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Savarese D, Boucher J and Corey B:
Glutamine treatment of paclitaxel-induced myalgias and arthralgias.
J Clin Oncol. 16:3918–3919. 1998.PubMed/NCBI
|
|
41
|
Savarese D, Savy G, Vahdat L, Wischmeyer P
and Corey B: Prevention of chemotherapy and radiation toxicity with
glutamine. Cancer Treat Rev. 29:501–513. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Strasser F, Demmer R, Böhme C, Schmitz SF,
Thuerlimann B, Cerny T and Gillessen S: Prevention of docetaxel- or
paclitaxel-associated taste alterations in cancer patients with
oral glutamine: a randomized, placebo-controlled, double-blind
study. Oncologist. 13:337–346. 2008. View Article : Google Scholar
|
|
43
|
Nozaki-Taguchi N, Chaplan S, Higuera E,
Ajakwe R and Yaksh T: Vincristine-induced allodynia in the rat.
Pain. 93:69–76. 2001. View Article : Google Scholar
|
|
44
|
Sarris A, Younes A, McLaughlin P, Moore D,
Hagemeister F, Swan F, Rodriguez M, Romaguera J, North L, Mansfield
P, et al: Cyclosporin A does not reverse clinical resistance to
paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin
Oncol. 14:233–239. 1996.
|
|
45
|
Martoni A, Zamagni C, Gheka A and Pannuti
F: Antihistamines in the treatment of taxol-induced paroxystic pain
syndrome. J Natl Cancer Inst. 85:67. 1993. View Article : Google Scholar : PubMed/NCBI
|
